We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Recipharm Increases Lyophilisation Capacity in Italy

Recipharm Increases Lyophilisation Capacity in Italy

Recipharm Increases Lyophilisation Capacity in Italy

Recipharm Increases Lyophilisation Capacity in Italy

Read time:

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Recipharm Increases Lyophilisation Capacity in Italy"

First Name*
Last Name*
Email Address*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Recipharm has announced a €3.7 million investment to expand its lyophilisation capacity in Masate, Italy, in response to growing customer demand. The investment forms part of Recipharm’s strategy to become a leading lyophilisation provider, and is in addition to the ongoing investment at Recipharm in Wasserburg, Germany, where a further €32 million is currently being spent to increase capacity.

Specialising in aseptic manufacturing and filling of parenterals, Recipharm in Masate, located close to Milan, offers lyophilisation capabilities in both vials and ampoules. The investment will see the introduction of a new lyophiliser for vials, bringing the total number of machines from five to six
and increasing the facility’s capacity by approximately 20 per cent.

The new machine will allow the CDMO to support more drug developers with their stability
challenges and meet growing demand for its lyophilisation services, particularly in Europe, China
and Japan.

Commenting on the investment, General Manager Giorgio Bruno said: “We are experiencing
greater demand for lyophilisation capabilities from our customers, ranging from some of the largest pharmaceutical companies to small and mid-sized firms. As we continue to receive more requests from existing customers and new enquiries from drug developers in new territories, we needed to increase our capacity”.